Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles (2021 - 2026)

Amylyx Pharmaceuticals' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $609000.0 for Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 64.24% year-over-year to $609000.0 in Q1 2026; TTM through Mar 2026 was $4.4 million, a 50.63% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 43.93% from the prior year.
• Amortizatization of Intangibles declined to $609000.0 in Q1 2026 per AMLX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $3.2 million in Q2 2024 and bottomed at -$2000.0 in Q1 2022.
• The 5-year median for Amortizatization of Intangibles is $1.8 million (2024), against an average of $1.6 million.
• Across the five-year window, Amortizatization of Intangibles jumped 145250.0% in 2023 and slumped 64.24% in 2026, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $1.9 million in 2022, then soared by 38.28% to $2.6 million in 2023, then sank by 30.37% to $1.8 million in 2024, then sank by 40.98% to $1.1 million in 2025, then sank by 42.38% to $609000.0 in 2026.
• Per Business Quant, the three latest AMLX Amortizatization of Intangibles figures stand at $609000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025).